Global Chemotherapy-Induced Neutropenia Treatment Market Size, Status and Forecast 2019-2025

Chemotherapy is widely used as to target the neoplastic cells. However, this therapy is effective against most of the cancer, but the cells of the hematopoietic system that produces billions of blood cells needed daily are highly sensitive to this therapy and result in loss of blood cell population. This condition is known as the chemotherapy-induced neutropenia. In chemotherapy-induced neutropenia, the body has a low level of neutrophils which are types of white blood cells. Neutrophils are body’s defense system against infections. Neutrophils fight against infection by destroying fungi, bacteria or yeast. Neutropenia occurs in about half of the people receiving chemotherapy. People with chemotherapy-induced neutropenia are most likely to develop infection and fever. It can also lead to delay in treatment and reduction in chemotherapy dose intensity. Chemotherapy-induced neutropenia is most likely to occur in cancer that directly affects the bone marrow such as leukemia. Chemotherapy-induced neutropenia patients mostly require hospitalization and cost of the treatment also increase with the anti-infective treatment.
Chemotherapy is the most preferred choice of treatment for cancer. Increasing use of chemotherapy will drive the growth of chemotherapy-induced neutropenia treatment market.
In 2018, the global Chemotherapy-Induced Neutropenia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Chemotherapy-Induced Neutropenia Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Chemotherapy-Induced Neutropenia Treatment development in United States, Europe and China.

The key players covered in this study
Amgen
Sanofi
Novartis
Baxter International
Teva Pharmaceuticals Industries
Apotex
Dr.Reddy’S Laboratory
Biogenomics
Ligand Pharmaceuticals
NAL Pharmaceuticals
Coherus BioSciences
Intas Pharmaceuticals

Market segment by Type, the product can be split into
Antibiotic Therapy
Colony-Stimulating Factor Therapy
Granulocyte Transfusion
Splenectomy Procedure
Others

Market segment by Application, split into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Chemotherapy-Induced Neutropenia Treatment status, future forecast, growth opportunity, key market and key players.
To present the Chemotherapy-Induced Neutropenia Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Chemotherapy-Induced Neutropenia Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions